Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of galactose oligosaccharide and derivatives thereof as drugs for preventing and treating non-alcoholic fatty acid disease (NAFLD)

A galactooligosaccharide and non-alcoholic technology, which is applied in the direction of drug combinations, medical preparations containing active ingredients, antibacterial drugs, etc., can solve problems such as potential safety hazards, and achieve high safety, significant liver fat accumulation, and products good stability effect

Pending Publication Date: 2020-07-10
OCEAN UNIV OF CHINA
View PDF18 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, although carrageenan and its oligosaccharides have antiviral activity as sprays (publication number CN102516323A, publication number CN104546895A), oral administration has certain potential safety hazards (Shang Q., Toxicol Let., 2017,279:87-95 ), agar gum, porphyra gum and their oligosaccharides are very safe when taken orally, and are high-quality raw materials for the development of marine drugs and functional foods

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of galactose oligosaccharide and derivatives thereof as drugs for preventing and treating non-alcoholic fatty acid disease (NAFLD)
  • Application of galactose oligosaccharide and derivatives thereof as drugs for preventing and treating non-alcoholic fatty acid disease (NAFLD)
  • Application of galactose oligosaccharide and derivatives thereof as drugs for preventing and treating non-alcoholic fatty acid disease (NAFLD)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Example 1: Containing 6-O-sulfate-β-1,3-D-galactose (Gal6S) and α-1,4-L-3,6-inner ether galactose (AnG) thiogaran oligosaccharide ( Preparation of SAOs), oligosaccharide alcohols (SAOs-OH) and oligosaccharide acids (SAOs-OOH).

[0039] Prepare 10mg / mL aqueous solution with dilute sulfuric acid with a molar concentration of 0.1M to 1g of sulfur agar polysaccharide, heat it to 60°C, stir and degrade it for 1.5 hours, neutralize it with a NaOH aqueous solution with a molar concentration of 2M after cooling, collect the supernatant by centrifugation, and then Add 3 times the volume of 95% medical ethanol (volume concentration) at 4°C overnight, centrifuge to collect the precipitate, dissolve it with a small amount of water, and then use a 200Da dialysis bag to desalt it. Take 100 mg of SAOs and dissolve it in 10 mL of 100 mM NaBH 4 The aqueous solution (containing NaOH with a molar concentration of 100 mM) was reacted overnight at 4°C, and the pH was adjusted to 7.0 by add...

Embodiment 2

[0044] Example 2: Laver gum oligosaccharides (PYOs), oligosaccharide alcohols (PYOs) containing β-1,3-D-galactose (Gal) and 6-O-sulfate-α-1,4-galactose (Gal6S) -OH) and oligosaccharide acids (PYOs-OOH).

[0045] Prepare laver gum with dilute sulfuric acid with a molar concentration of 0.1M to form a 10mg / mL aqueous solution, heat it to 80°C, stir and degrade it for 2 hours, neutralize it with an aqueous NaOH solution with a molar concentration of 2M after cooling, collect the supernatant by centrifugation, and add 4 times the volume 95% medical ethanol was overnight at 4°C, the precipitate was collected by centrifugation and dissolved with a small amount of water, desalted with a 200Da dialysis bag, concentrated by rotary evaporation, and freeze-dried to obtain PYOs (such as figure 1 shown in A-D). Take 150 mg of PYOs oligosaccharides and dissolve it in 15 mL of NaBH with a molar concentration of 150 mM 4 The aqueous solution (containing NaOH with a molar concentration of 15...

Embodiment 3

[0050] Example 3: Agar oligosaccharides containing β-1,3-D-galactose (Gal) and α-1,4-L-3,6-galactose (AnG) and their oligosaccharide alcohols and oligosaccharides acid preparation.

[0051] Dissolve the agarose in hot water, use dilute hydrochloric acid with a molar concentration of 0.1M to prepare a 10mg / mL solution, stir and degrade it at 80°C for 0.5 hours, neutralize it with an aqueous NaOH solution with a molar concentration of 2M after cooling, collect the supernatant by centrifugation, and then Add 3.5 times the volume of 95% medical ethanol at 4°C overnight, collect the precipitate by centrifugation, dissolve it in water, use a 200Da dialysis bag to dialyze and desalt, concentrate by rotary evaporation and freeze-dry to obtain agar oligosaccharide AOs, and further reduce it with sodium borohydride to obtain agar oligosaccharide Alcohol AOs-OH, or agarooligosaccharide acid AOs-OOH obtained by oxidation with Benedict's reagent. The chemical structural formulas of agar o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of marine drugs and particularly relates to application of galactose oligosaccharide containing D-galactose and L-galactose and derivatives thereof as drugs for preventing and treating non-alcoholic fatty acid disease (NAFLD). Red alga polysaccharide containing D / L-galactose as a raw material, controllable degradation is performed through a physical method, a chemical method, a biological enzyme method or any combination of the methods, galactose oligosaccharide and derivatives thereof with different polymerization degrees are prepared, and molecular frameworks contain D-galactose and L-galactose derivatives. The raw materials of the products come from red alga polysaccharide, the products have the advantages that resources are rich, the preparation process is simple, high safety, prone to industrialization and the like, and the products as prebiotics and functional factors have broad application prospects in the development fields of improvement of intestinal flora disorder of NAFLD patients, prevention and treatment of NAFLD caused by high fat diet and liver protection, fat reduction, weight losing and special medical food.

Description

technical field [0001] The invention belongs to the field of marine drugs, and in particular relates to the application of an oligosaccharide containing D-galactose and L-galactose and its derivatives as a drug for preventing and treating nonalcoholic fatty liver. Background technique [0002] Nonalcoholic fatty liver disease (NAFLD), the hepatic manifestation of metabolic syndrome, is the most common chronic liver disease worldwide. NAFLD is defined as a clinicopathological syndrome characterized by abnormal accumulation of fat in the liver, excluding excessive alcohol consumption, viral infection, or other liver diseases. NAFLD consists of a spectrum of liver diseases, including simple hepatic steatosis, nonalcoholic steatohepatitis (NASH), and NASH-associated cirrhosis and hepatocellular carcinoma. With the global obesity epidemic, the incidence of NAFLD is increasing and it is now the most common chronic liver disease worldwide. NAFLD is a liver disease associated with...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/702A61K31/715A61P1/16A61P3/06A61P31/04A61P31/02
CPCA61K31/702A61K31/715A61P1/16A61P3/06A61P31/04A61P31/02
Inventor 于广利王学良蒋昊蔡超
Owner OCEAN UNIV OF CHINA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com